Weighted Average Number of Shares Outstanding, Diluted of Intra-Cellular Therapies, Inc. from 31 Dec 2020 to 31 Dec 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Intra-Cellular Therapies, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Dec 2020 to 31 Dec 2024.
  • Intra-Cellular Therapies, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Dec 2024 was 103,131,017, a 7.6% increase year-over-year.
  • Intra-Cellular Therapies, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 103,131,017, a 7.6% increase from 2023.
  • Intra-Cellular Therapies, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 95,881,729, a 2% increase from 2022.
  • Intra-Cellular Therapies, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 94,046,670, a 16% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Intra-Cellular Therapies, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 103,131,017 +7,249,288 +7.6% 01 Oct 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
Q3 2024 105,768,386 +9,625,303 +10% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2024 2024 Q3
Q2 2024 103,723,007 +7,774,944 +8.1% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 96,875,275 +1,740,581 +1.8% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 95,881,729 +1,835,059 +2% 01 Oct 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
Q3 2023 96,143,083 +1,626,289 +1.7% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 95,948,063 +1,662,946 +1.8% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 95,134,694 +2,530,404 +2.7% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 94,046,670 01 Oct 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
Q3 2022 94,516,794 +13,162,070 +16% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 94,285,117 +13,055,329 +16% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 92,604,290 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q3 2021 81,354,724 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 81,229,788 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2

Intra-Cellular Therapies, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 103,131,017 +7,249,288 +7.6% 01 Jan 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
2023 95,881,729 +1,835,059 +2% 01 Jan 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
2022 94,046,670 +12,793,276 +16% 01 Jan 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
2021 81,253,394 +10,888,594 +15% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
2020 70,364,800 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.